93 related articles for article (PubMed ID: 19558864)
21. Nasopharyngeal mucosal changes in EB virus VCA-IgA antibody positive persons.
Li EJ; Tan BF; Zeng Y; Wang PZ; Zhong JM; Deng H; Zhu CS; Wei JN; Pan WJ
Chin Med J (Engl); 1985 Jan; 98(1):25-30. PubMed ID: 2988864
[No Abstract] [Full Text] [Related]
22. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
23. [Clinical analysis and long-term follow up study of asymptomatic nasopharyngeal carcinoma patients].
Ji MF; Guo YQ; Zheng SA; Liang JS; Wang DK; Ou XT
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):53-6. PubMed ID: 12778770
[TBL] [Abstract][Full Text] [Related]
24. [Value of Epstein-Barr virus serology during radiotherapy of undifferentiated carcinoma of the nasopharynx].
Yomi J; Fouda A; Fossi A; Bejanga B
Bull Cancer Radiother; 1996; 83(3):168-9. PubMed ID: 8977568
[No Abstract] [Full Text] [Related]
25. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma.
Ng MH; Chan KH; Ng SP; Zong YS
Ai Zheng; 2006 Feb; 25(2):250-6. PubMed ID: 16480597
[TBL] [Abstract][Full Text] [Related]
27. [Dynamic observation on serum sialic acid in nasopharyngeal carcinoma patients].
Zhang HQ; Zhou ZB; Fan L; Jin F; Fei Y; Li XH; Zhao HY
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Jun; 40(6):411-4. PubMed ID: 16144331
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of Epstein-Barr virus-related diseases.
Linde A
Scand J Infect Dis Suppl; 1996; 100():83-8. PubMed ID: 8860358
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus and nasopharyngeal cancer.
Poole E; Stewart IA
N Z Med J; 1984 Apr; 97(753):239. PubMed ID: 6326009
[No Abstract] [Full Text] [Related]
30. Nasopharyngeal carcinoma and Epstein-Barr virus--associated serologic markers.
Tam JS; Murray HG
Ear Nose Throat J; 1990 Apr; 69(4):261-7. PubMed ID: 2161732
[TBL] [Abstract][Full Text] [Related]
31. Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis.
Li Z; Bian LJ; Li Y; Liang YJ; Liang HZ
Pathol Res Pract; 2009; 205(8):542-50. PubMed ID: 19269113
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
33. [Observation on three kinds of virus infection of the patients suffering from nasopharyngeal carcinoma and heroin addicts].
Huang GW; Li F; Liang G
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Dec; 41(12):951-2. PubMed ID: 17345713
[No Abstract] [Full Text] [Related]
34. Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma.
Dimery IW; Jacobs C; Tseng A; Saks S; Pearson G; Hong WK; Gutterman JU
J Biol Response Mod; 1989 Jun; 8(3):221-6. PubMed ID: 2545832
[TBL] [Abstract][Full Text] [Related]
35. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma.
Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY
Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423
[TBL] [Abstract][Full Text] [Related]
36. Squamous carcinoma of the nasopharynx.
Moloy PJ; Chung YT; Krivitsky PB; Kim RC
West J Med; 1985 Jul; 143(1):66-9. PubMed ID: 2994305
[TBL] [Abstract][Full Text] [Related]
37. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong.
Lo S; Ho WK; Wei WI
Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561
[TBL] [Abstract][Full Text] [Related]
38. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
[No Abstract] [Full Text] [Related]
39. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies in Epstein-Barr virus-related nasopharyngeal carcinoma: prognostic and therapeutic implications.
Levine PH; Pearson GR
J Exp Pathol; 1987; 3(4):329-33. PubMed ID: 2842473
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
